Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its...
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext...
Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production LEUVEN, BELGIUM - July 8, 2024 – 6:30 pm, Oxurion NV...
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024. Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET, Oxurion NV (Euronext...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in...
Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: